Voltarol Emulgel
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT
Voltarol Emulgel® P
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Diethylammonium-{-o-[2,6-dichlorophenyl)-amino]-phenyl}-acetate.
100g of Voltarol Emulgel P contains 1.16g of the active substance diclofenac diethylammonium, which corresponds to 1g diclofenac sodium.
For excipients, see section 6.1
3 PHARMACEUTICAL FORM
Gel for topical administration.
White to practically white, soft, homogeneous, cream-like
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
For the local symptomatic relief of pain and inflammation in:
- trauma of the tendons, ligaments, muscles and joints, e.g. due to sprains, strains and bruises
- localised forms of soft tissue rheumatism
For the relief of pain of non-serious arthritic conditions.
4.2 Posology and method of administration
Adults and children 14 years and over: Voltarol Emulgel P should be rubbed gently into the skin. Depending on the size of the affected site to be treated, 24g (a circular shaped mass approximately 2.0-2.5cm in diameter) should be applied 3-4 times a day. The maximum daily dose is 16g. Therefore the maximum weekly dose is 112g.
For arthritis pain it may be necessary to apply the gel for up to 7 days (to allow its effect to build up on the joint) before an improvement in pain is noticed. The gel can be used for up to 14 days under pharmacy supervision.
After application, the hands should be washed unless they are the site being treated.
If symptoms do not improve by day 7, or if they worsen within the first 7 days, a consultation with a doctor is recommended. Consultation with a doctor is recommended if more than two major joints in the body are affected. Do not use for more than 14 days unless recommended by a doctor.
Use in the elderly: The usual adult dosage may be used.
Children and adolescents: There are insufficient data on efficacy and safety available for the children and adolescents below 14 years of age (see also contraindications section 4.3). In children aged 14 years and over, if this product is required for more than 7 days for pain relief or if the symptoms worsen the patient/parents of the adolescent is/are advised to consult a doctor.
4.3 Contraindications
• Patients with or without chronic asthma in whom attacks of asthma, urticaria or acute rhinitis are precipitated by acetylsalicylic acid (aspirin) or other non-steroidal anti-inflammatory drugs (NSAIDs).
• Hypersensitivity to diclofenac, acetylsalicylic acid other non-steroidal antiinflammatory drugs or any of the excipients.
• Third trimester of pregnancy.
• Concomitant use of other products containing diclofenac.
• Concomitant use of oral NSAIDS.
• The use in children and adolescents aged less than 14 years is
contraindicated.
4.4 Special warnings and precautions for use
The possibility of systemic adverse events from application of Voltarol Emulgel P cannot be excluded if the preparation is used on large areas of skin and over a prolonged period (see the product information on systemic forms of diclofenac).
Voltarol Emulgel P should be applied only to intact, non-diseased skin and not to skin wounds or open injuries. It should not be allowed to come into contact with the eyes or mucous membranes, and should not be ingested.
Discontinue the treatment if a skin rash develops after applying the product.
Patients with a history of, or active, peptic ulceration. Some possibility of gastro-intestinal bleeding in those with a significant history of this condition has been reported in isolated cases.
Like other drugs that inhibit prostaglandin synthetase activity, diclofenac and other NSAIDs can precipitate bronchospasm if administered to patients suffering from or with a previous history of, bronchial asthma.
Voltarol Emulgel P contains propylene glycol, which may cause mild localised skin irritation in some people.
Voltarol Emulgel P can be used with non-occlusive bandages but should not be used with an airtight occlusive dressing.
4.5 Interaction with other medicinal products and other forms of interaction
Since systemic absorption of diclofenac from topical application is very low, such interactions are very unlikely.
No drug interactions during treatment with Voltarol Emulgel P have been reported, but the following have been observed with oral forms of diclofenac or other NSAIDs.
Lithium and digoxin: Voltarol may increase plasma concentrations of lithium and digoxin.
Anticoagulants: Although clinical investigations do not appear to indicate that Voltarol has an influence on the effect of anticoagulants, there are isolated reports of an increased risk of haemorrhage with the combined use of diclofenac and anticoagulant therapy. Therefore, to be certain that no change in anticoagulant dosage is required, close monitoring of such patients is required. As with other non-steroidal anti-inflammatory agents, diclofenac in a high dose can reversibly inhibit platelet aggregation.
Antidiabetic agents: Clinical studies have shown that Voltarol can be given together with oral antidiabetic agents without influencing their clinical effect. However there have been isolated reports of hypoglycaemic and hyperglycaemic effects which have required adjustment to the dosage of hypoglycaemic agents.
Ciclosporin: Cases of nephrotoxicity have been reported in patients receiving concomitant cyclosporin and NSAIDs, including diclofenac. This might be mediated through combined renal antiprostaglandin effects of both the NSAID and cyclosporin.
Methotrexate: Cases of serious toxicity have been reported when methotrexate and NSAIDs are given within 24 hours of each other. This interaction is mediated through accumulation of methotrexate resulting from impairment of renal excretion in the presence of the NSAID.
Quinolone antimicrobials: Convulsions may occur due to an interaction between quinolones and NSAIDs. This may occur in patients with or without a previous history of epilepsy or convulsions. Therefore, caution should be exercised when considering the use of a quinolone in patients who are already receiving an NSAID.
Other NSAIDs and steroids: Co-administration of Voltarol with other systemic NSAIDs and steroids may increase the frequency of unwanted effects. Concomitant therapy with aspirin lowers the plasma levels of each, although no clinical significance is known.
Diuretics: Various NSAIDs are liable to inhibit the activity of diuretics. Concomitant treatment with potassium-sparing diuretics may be associated with increased serum potassium levels, hence serum potassium should be monitored.
Mifepristone: NSAIDs should not be used for 8-12 days after mifepristone administration as NSAIDs can reduce the effects of mifepristone.
Anti-hypertensives: Concomitant use of NSAIDs with antihypertensive drugs (i.e. beta-blockers, angiotensin converting enzyme (ACE) inhibitors, diuretics) may cause a decrease in their antihypertensive effect via inhibition of vasodilatory prostaglandin synthesis.
4.6 Fertility, Pregnancy and lactation Pregnancy
The systemic concentration of diclofenac is lower after topical administration, compared to oral formulations. With reference to experience from treatment with NSAIDs with systemic uptake, the following is recommended:
Inhibition of prostaglandin synthesis may adversely affect the pregnancy and/or the embryo/fetal development. Data from epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk for cardiovascular malformation was increased from less than 1%, up to approximately 1.5 %. The risk is believed to increase with dose and duration of therapy. In animals, administration of a prostaglandin synthesis inhibitor has been shown to result in increased pre-and post-implantation loss and embryo-fetal lethality. In addition, increased incidences of various malformations, including cardiovascular, have been reported in animals given a prostaglandin synthesis inhibitor during the organogenetic period. During the first and second trimester of pregnancy, diclofenac should not be given unless clearly necessary. If diclofenac is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low and duration of treatment as short as possible.
During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the fetus to:
- cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension);
- renal dysfunction, which may progress to renal failure with oligo-hydroamniosis;
The mother and the neonate, at the end of pregnancy, to:
- possible prolongation of bleeding time, an anti-aggregating effect which may occur even at very low doses.
- inhibition of uterine contractions resulting in delayed or prolonged labour.
Consequently, diclofenac is contraindicated during the third trimester of pregnancy.
Lactation
Like other NSAIDs, diclofenac passes into breast milk in small amounts. However, at therapeutic doses of Voltarol Emulgel P no effects on the suckling child are anticipated. Because of a lack of controlled studies in lactating women, the product should only be used during lactation under advice from a healthcare professional. Under this circumstance, Voltarol Emulgel P should not be applied on the breasts of nursing mothers, nor elsewhere on large areas of skin or for a prolonged period of time (see section 4.4).
4.7 Effects on ability to drive and use machines
Cutaneous application of Voltarol Emulgel P has no or negligible influence on the ability to drive and use machines.
4.8 Undesirable effects
Local:
Voltarol Emulgel P is usually well tolerated. Local irritation, erythema, pruritus or dermatitis may occasionally occur. Skin photosensitivity, desquamation, discolouration and bullous or vesicular eruptions have been reported in isolated cases. Patients should be warned against excessive exposure to sunlight in order to reduce the incidence of photosensitivity.
General:
Systemic absorption of Voltarol Emulgel P is low compared with plasma levels obtained following oral forms of diclofenac. However, where Voltarol Emulgel P is applied to a relatively large area and over a prolonged period, the possibility of systemic side effects cannot be completely excluded.
Asthma has been rarely reported in patients using topical NSAID preparations.
Adverse reactions (Table 1) are ranked under heading of frequency, the most frequent first, using the following convention: very common (> 1/10); common (> 1/100, < 1/10); uncommon (> 1/1,000, < 1/100); rare (> 1/10,000, < 1/1,000); very rare (< 1/10,000), not known: cannot be estimated from the available data .
Table 1
|
Immune system disorder: | |
|
Very rare: |
Hypersensitivity (including urticaria), angioneurotic oedema. |
|
Infections and infestations: | |
|
Very rare: |
Rash pustular. |
|
Respiratory, thoracic and mediastinal disorders | |
|
Very rare: |
Asthma. |
|
Skin and subcutaneous tissue disorders | |
|
Common: |
Rash, eczema, erythema, dermatitis (including dermatitis contact), pruritus |
|
Rare: |
Dermatitis bullous |
|
Very rare: |
Photosensitivity reaction |
General: Systemic absorption of Voltarol Emulgel P is low compared with plasma levels obtained following administration of oral forms of Voltarol and the likelihood of systemic side-effects occurring with topical diclofenac is small compared with the frequency of side-effects associated with oral diclofenac. However, where Voltarol Emulgel P is applied to a relatively large area of skin and over a prolonged period, the possibility of systemic side-effects cannot be completely excluded. If such usage is envisaged, the data sheet on Voltarol oral dosage forms should be consulted.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at:www.mhra. gov.uk/yel l owcard.
Overdose
4.9
Signs and symptoms
The low systemic absorption of topical diclofenac renders overdose very unlikely. However, undesirable effects, similar to those observed following an overdose of diclofenac tablets, can be expected if Voltarol Emulgel P is inadvertently ingested (1 tube of 100g contains the equivalent of 1000mg of diclofenac sodium). In the event of accidental ingestion, resulting in significant systemic adverse effects, general therapeutic measures normally adopted to treat poisoning with non-steroidal anti-inflammatory medicines should be used. Gastric decontamination and the use of activated charcoal should be considered, especially within a short time of ingestion.
Treatment
Management of overdosage with NSAIDs essentially consists of supportive and symptomatic measures. There is no typical clinical picture resulting from diclofenac overdosage. Supportive and symptomatic treatment should be given for complications such as hypotension, renal failure, convulsions, gastrointestinal irritation, and respiratory depression; specific therapies such as forced diuresis, dialysis or haemoperfusion are probably of no help in eliminating NSAIDs due to their high rate of protein binding and extensive metabolism.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Voltarol Emulgel P is an anti-inflammatory and analgesic preparation designed for external application. Due to an aqueous-alcoholic base the gel exerts a soothing and cooling effect.
5.2 Pharmacokinetic properties
When Emulgel P is applied locally, the active substance is absorbed through the skin. In healthy volunteers approximately 6% of the dose applied is absorbed when determined by urinary excretion of diclofenac and its hydroxylated metabolites. Findings in patients confirm that diclofenac penetrates inflamed areas following local application of Emulgel P.
Synovial fluid and tissue levels of diclofenac are higher than those detected in plasma.
Preclinical safety data
5.3
None known.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Diethylamine, carbomers, cetomacrogol, cocoyl capryloccaprate, isopropyl alcohol, liquid paraffin, perfume creme 45 (containing benzyl benzoate), propylene glycol, purified water.
6.2 Incompatibilities
None stated.
6.3 Shelf life
Three years.
6.4 Special precautions for storage
All presentations: Do not store above 30°C.
Pump dispenser presentation: The pump dispenser is a pressurised container. It should be protected from direct sunlight and must not be pierced or burned even when empty.
Voltarol Emulgel P should be kept out of reach of children.
6.5
Nature and contents of containers
Sealed aluminium tubes with protective inner coating, closed with a polypropylene screw cap, available in packs of 10g, 30g, 50g and 100, 120g, 150g and 180g.
Aluminium laminated tube (low density polyethylene / aluminium / high density polyethylene (internal layer)) fitted with a high density polyethylene shoulder and closed by a moulded seal. The tube is closed with a polypropylene screw cap in white or blue, with two alternate shapes of cap and thread, incorporating a moulded feature used to insert, twist and remove the seal before first use. Available in packs of 30g, 50g, 100g, 120g ,150g and 180g (not all packs may be marketed).
Pump dispenser with aluminium can, valve (high density polyethylene, reinforced with titanium dioxide) with multi-layer pouch (low density polyethylene), mounted with a protective cap. Available in packs of 75ml.
6.6 Special precautions for disposal
None
7 MARKETING AUTHORISATION HOLDER
GlaxoSmithKline Consumer Healthcare (UK) Trading Limited,
980 Great West Road
Brentford
Middlesex
TW8 9GS
United Kingdom
8 MARKETING AUTHORISATION NUMBER(S)
PL 44673/0155
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION 1 April 2000
10 DATE OF REVISION OF THE TEXT
08/07/2016